Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Akustische OSA-Vorhersage im Wachzustand und Überwachung im Schlaf

25. September 2026 aktualisiert von: University of Manitoba

The purpose of this study is to investigate the feasibility of sound analysis for: a) sleep apnea detection both during wakefulness and sleep, and b) flow-sound relationship during both wakefulness and sleep in patients and control individuals. The ultimate goal of our research is to simplify the current assessments for sleep apnea detection so that it is more convenient for patients and also much faster than the current techniques.

Studienübersicht

Status

Rekrutierung

Bedingungen

Detaillierte Beschreibung

Sleep apnea, in particular obstructive sleep apnea (OSA), is one of the most common breathing disorders and is associated with major comorbidities such as higher risk perioperative complications. This is particularly concerning given that about 40-80% of people with moderate-severe OSA remain undiagnosed. Due to the resource-intensive assessments required to diagnose OSA and the significantly increased risk of car accidents and perioperative complications associated with undiagnosed OSA, there is a critical need to develop a more effective method to screen for OSA quickly and reliably.

The most widely used clinical OSA screening tool is the STOP-Bang questionnaire, which is a quick and easy-to-implement inquiry form that has a high sensitivity to detect moderate and severe OSA (>93%), but it has a very high rate of false positives (>63%). Thus, a significant number of patients without OSA will continue to be referred for PSG, which contributes to a strain on the healthcare system. Therefore, a quick and reliable screening tool for OSA and its severity during wakefulness is very appealing but challenging, as people with OSA do not show any apparent symptoms during wakefulness.

We have developed a novel screening algorithm for OSA based on the analysis of tracheal breathing sounds recorded from an individual during wakefulness, called AWakeOSA. It can predict OSA with a sensitivity (86%) similar to STOP-Bang, but with a much higher specificity (84%) for detecting individuals without OSA. The AWakeOSA technology still needs significant research and quality improvements to become a reliable home-care device for screening under unsupervised conditions, which is the central purpose of this project. In addition, we are interested to investigate the breathing sound changes from wakefulness to sleep in both groups of healthy and apneic population. For that, we need to record PSG data and breathing sounds during sleep in addition to recording breathing sounds during wakefulness.

We have also designed a specialized hardware device, called ASAD-3, capable of recording breathing sounds with high quality during both wakefulness (short-period recording) and during sleep (long hours recording) that uses two small microphones that are placed in contact with the skin over the trachea and lung, respectively. The hardware device will be utilized to optimize the AWakeOSA algorithm and work towards achieving a reliable home-care device for screening under unsupervised conditions.

The proposed technology will enable a reliable and quick diagnosis of OSA that can be either used in a clinician's office during wakefulness and/or used at home by people to monitor their own OSA. The outcomes of this study will benefit the health care system and society significantly as it will: 1) reduce the financial burden of OSA on the healthcare system by reducing the need for PSG and unnecessary preoperative resources; and 2) provide a quick and reliable personal OSA home-care monitoring system for better OSA treatment management.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

250

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

OSA Participants of this study will be anyone regardless of their sex, gender or ethnic background, who are suspected of OSA and meet the inclusion/exclusion criteria. In addition, we will record up to 50 healthy controls.

Beschreibung

Inclusion Criteria:

  • 1) age between 18 to 70 years.
  • 2) suspected of OSA and referred to full PSG study by a doctor.

Exclusion Criteria:

  • 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders.
  • 2) having insomnia or restless leg.
  • 3) drug addiction.
  • 4) under the current, direct supervision of the PI of this study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: CASE_CONTROL
  • Zeitperspektiven: RETROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
OSA Participants

Inclusion Criteria: 1) age between 18 to 70 years; 2) suspected of OSA and referred to full PSG study by a doctor.

Exclusion Criteria: 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders; 2) having insomnia or restless leg; 3) drug addiction; and 4) under the current, direct supervision of the PI of this study.

Healthy Controls

Inclusion Criteria: 1) age between 18 to 70 years; 2) non-snorer, and being free of any sleep disorders.

Exclusion Criteria: same as the OSA Participants. All participants must not have any cold or any other respiratory illness at the time of recording.

Illiterate participants may still participate in the study; however, there must be a witness who is not involved in the study (i.e. PI, Co-PI, study coordinator, research assistants (RA)/students, etc.) present to witness the consent process between the participant and the individual obtaining consent.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
OSA Severity
Zeitfenster: 1 Day

Data recorded during wakefulness will be analyzed using our published AWakeOSA algorithm to classify the participants into two groups of those who have AHI below and above 15. We will also run Multivariate statistical analysis to find the main effect of OSA severity (AHI) on the sound features and their interaction with the anthropometric information.

1 Day

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Acoustic AHI correlation to PSG
Zeitfenster: 1 Day

For the sleep data, we will find the correlation of the AHI values estimated by our acoustic device using our previous algorithm compared to those of the Polysomnogram (PSG).

1 Day

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Zahra Kazem-Moussavi, Ph.D., University of Manitoba

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Oktober 2021

Primärer Abschluss (Geschätzt)

1. September 2028

Studienabschluss (Geschätzt)

23. Dezember 2028

Studienanmeldedaten

Zuerst eingereicht

30. September 2019

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

30. September 2019

Zuerst gepostet (Tatsächlich)

2. Oktober 2019

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

30. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • B2018:094

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .